EP2967049A4 - Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine - Google Patents
Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine Download PDFInfo
- Publication number
- EP2967049A4 EP2967049A4 EP14763703.7A EP14763703A EP2967049A4 EP 2967049 A4 EP2967049 A4 EP 2967049A4 EP 14763703 A EP14763703 A EP 14763703A EP 2967049 A4 EP2967049 A4 EP 2967049A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiotensin
- compositions
- compounds
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015427 Angiotensins Human genes 0.000 title 1
- 108010064733 Angiotensins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/52—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20188953.2A EP3935944A1 (fr) | 2013-03-15 | 2014-03-15 | Composés pour le traitement des maladies musculo-squelettiques |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802259P | 2013-03-15 | 2013-03-15 | |
US201361809290P | 2013-04-05 | 2013-04-05 | |
PCT/US2014/030071 WO2014145331A1 (fr) | 2013-03-15 | 2014-03-15 | Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20188953.2A Division EP3935944A1 (fr) | 2013-03-15 | 2014-03-15 | Composés pour le traitement des maladies musculo-squelettiques |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2967049A1 EP2967049A1 (fr) | 2016-01-20 |
EP2967049A4 true EP2967049A4 (fr) | 2017-01-11 |
EP2967049B1 EP2967049B1 (fr) | 2020-09-02 |
Family
ID=51537955
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20188953.2A Pending EP3935944A1 (fr) | 2013-03-15 | 2014-03-15 | Composés pour le traitement des maladies musculo-squelettiques |
EP14763703.7A Active EP2967049B1 (fr) | 2013-03-15 | 2014-03-15 | Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20188953.2A Pending EP3935944A1 (fr) | 2013-03-15 | 2014-03-15 | Composés pour le traitement des maladies musculo-squelettiques |
Country Status (13)
Country | Link |
---|---|
US (2) | US9732074B2 (fr) |
EP (2) | EP3935944A1 (fr) |
JP (1) | JP6480909B2 (fr) |
KR (1) | KR102230461B1 (fr) |
CN (1) | CN105451554B (fr) |
AU (1) | AU2014233185B2 (fr) |
CA (1) | CA2911376C (fr) |
DK (1) | DK2967049T3 (fr) |
ES (1) | ES2834430T3 (fr) |
HK (1) | HK1220324A1 (fr) |
NZ (1) | NZ712479A (fr) |
RU (1) | RU2688163C2 (fr) |
WO (1) | WO2014145331A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ712479A (en) * | 2013-03-15 | 2019-01-25 | Univ Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
CA2902619A1 (fr) | 2013-03-15 | 2014-09-25 | University Of Southern California | Methodes de traitement de la sclerose en plaques |
MX2015016143A (es) * | 2013-05-24 | 2016-03-31 | Tarix Pharmaceuticals Ltd | Peptidos de angiotensina para tratar el sindrome de marfan y transtornos relacionados. |
CN107073295A (zh) * | 2014-07-17 | 2017-08-18 | 南加利福尼亚大学 | 用于治疗肌骨病的方法、化合物和组合物 |
AR108906A1 (es) | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
WO2018231614A1 (fr) * | 2017-06-16 | 2018-12-20 | Gaffney Kevin J | Procédés de traitement de lupus érythémateux disséminé |
WO2019027890A1 (fr) * | 2017-08-04 | 2019-02-07 | Gaffney Kevin J | Méthodes de traitement de la myélosuppression |
WO2019036267A1 (fr) * | 2017-08-16 | 2019-02-21 | Gaffney Kevin J | Compositions pour augmenter les cellules souches mésenchymateuses circulantes |
JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
US11833148B2 (en) | 2018-05-11 | 2023-12-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating or limiting development of cardiovascular disease-related neurological disorders |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
WO2021189038A1 (fr) * | 2020-03-20 | 2021-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Ang-1-7 en tant qu'agent thérapeutique contre le coronavirus |
CA3209749A1 (fr) * | 2021-01-28 | 2022-08-04 | Capacity Bio, Inc. | Procedes et agents qui stimulent le renouvellement mitochondrial pour traiter une maladie |
EP4220172A1 (fr) | 2022-01-27 | 2023-08-02 | Université Libre de Bruxelles | Covid-19 théranostique |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001389A1 (fr) * | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides en tant que doubles antagonistes de recepteurs d'angiotensine et d'endotheline |
US20080318951A1 (en) * | 2007-06-05 | 2008-12-25 | Theravance, Inc. | Dual-acting benzoimidazole antihypertensive agents |
US20110009409A1 (en) * | 2009-07-07 | 2011-01-13 | Blair Brooke | Dual-acting pyrazole antihypertensive agents |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
EP0668864A1 (fr) * | 1992-07-17 | 1995-08-30 | Merck & Co. Inc. | Biphenylmethylimidazopyridines substituees |
US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
US5834432A (en) | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
ES2311571T3 (es) * | 1996-04-12 | 2009-02-16 | G.D. Searle Llc | Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2. |
AUPO089396A0 (en) | 1996-07-09 | 1996-08-01 | Howard Florey Institute Of Experimental Physiology And Medicine | Neuroactive peptide |
US6110895A (en) | 1996-12-16 | 2000-08-29 | University Of Southern California | Method of promoting healing in skin grafts |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
CA2315266C (fr) | 1997-12-12 | 2004-08-10 | University Of Southern California | Compositions de cicatrisation |
CA2319701C (fr) | 1998-02-09 | 2009-09-29 | University Of Southern California | Procede pour promouvoir l'erythropoiese |
WO1999042123A1 (fr) | 1998-02-19 | 1999-08-26 | University Of Southern California | Procede pour favoriser la proliferation et la differentiation des neurones |
US7173011B2 (en) | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
US6455500B1 (en) | 1998-03-10 | 2002-09-24 | University Of Southern California | Radiation therapy methods |
US6498138B1 (en) | 1998-03-11 | 2002-12-24 | University Of Southern California | Method of promoting production of living tissue equivalents |
US6762167B1 (en) | 1998-05-11 | 2004-07-13 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
AU759285B2 (en) | 1998-05-11 | 2003-04-10 | University Of Southern California | Methods to increase white blood cell survival after chemotherapy |
US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
JP3686335B2 (ja) | 1998-07-13 | 2005-08-24 | ユニヴァースティ オブ サザーン カリフォルニア | 骨および軟骨成長と修復を促進する方法 |
EP1105149A1 (fr) | 1998-08-13 | 2001-06-13 | University Of Southern California | Procede pour augmenter le debit sanguin vers le tissu ischemique |
US6730775B1 (en) | 1999-03-23 | 2004-05-04 | University Of Southern California | Methods for limiting scar and adhesion formation |
US7338938B2 (en) | 1999-05-10 | 2008-03-04 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
US6747008B1 (en) | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
WO2002087504A2 (fr) | 2001-05-01 | 2002-11-07 | University Of Southern California | Methodes d'inhibition de la proliferation des cellules tumorales |
JP4707321B2 (ja) * | 2001-05-31 | 2011-06-22 | ヴィコール・ファルマ・アーベー | アンギオテンシンiiアゴニストとして有用な三環式化合物 |
BRPI0105509B8 (pt) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
WO2008130217A1 (fr) | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Analogues d'angiotensines cycliques |
TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
RU2010113992A (ru) | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение урокортина и кортиколиберина в качестве терапевтических средств |
WO2011011232A1 (fr) * | 2009-07-22 | 2011-01-27 | Theravance, Inc. | Agents antihypertenseurs à double action à base d'oxazole |
RU2521251C2 (ru) * | 2009-11-06 | 2014-06-27 | Аэрпио Терапьютикс Инк. | Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа |
AU2011205485B2 (en) * | 2010-01-13 | 2014-09-25 | Glaxosmithkline Llc | Compounds and methods |
WO2011090929A1 (fr) * | 2010-01-19 | 2011-07-28 | Theravance, Inc. | Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action |
EA022388B1 (ru) | 2010-03-26 | 2015-12-30 | Университи Оф Сатерн Калифорния | Способы лечения комбинированных лучевых и тепловых поражений |
CN102858360B (zh) | 2011-02-02 | 2017-07-25 | 南加利福尼亚大学 | 治疗糖尿病足溃疡的方法 |
WO2012135597A2 (fr) * | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Nouveau récepteur, anti-inflammatoire, protecteur et son utilisation dans conservation de fonction mitochondriale, cicatrisation et réparation de lésions |
US9688724B2 (en) | 2012-05-14 | 2017-06-27 | University Of Southern California | Methods for limiting development of a skin wound |
WO2014116587A1 (fr) | 2013-01-23 | 2014-07-31 | University Of Southern California | Stimulation de vaccination par des peptides d'angiotensine |
NZ712479A (en) | 2013-03-15 | 2019-01-25 | Univ Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
RU2674148C2 (ru) | 2013-04-30 | 2018-12-05 | Юниверсити Оф Саузерн Калифорния | Ускоренное заживление повреждений глаз с помощью ангиотензиновых пептидов |
-
2014
- 2014-03-15 NZ NZ712479A patent/NZ712479A/en unknown
- 2014-03-15 CN CN201480027988.9A patent/CN105451554B/zh active Active
- 2014-03-15 ES ES14763703T patent/ES2834430T3/es active Active
- 2014-03-15 CA CA2911376A patent/CA2911376C/fr active Active
- 2014-03-15 KR KR1020157029160A patent/KR102230461B1/ko active IP Right Grant
- 2014-03-15 WO PCT/US2014/030071 patent/WO2014145331A1/fr active Application Filing
- 2014-03-15 AU AU2014233185A patent/AU2014233185B2/en active Active
- 2014-03-15 RU RU2015138801A patent/RU2688163C2/ru active
- 2014-03-15 EP EP20188953.2A patent/EP3935944A1/fr active Pending
- 2014-03-15 US US14/773,041 patent/US9732074B2/en active Active
- 2014-03-15 JP JP2016503327A patent/JP6480909B2/ja active Active
- 2014-03-15 DK DK14763703.7T patent/DK2967049T3/da active
- 2014-03-15 EP EP14763703.7A patent/EP2967049B1/fr active Active
-
2016
- 2016-07-08 HK HK16108005.8A patent/HK1220324A1/zh unknown
-
2017
- 2017-07-12 US US15/648,184 patent/US10301298B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001389A1 (fr) * | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides en tant que doubles antagonistes de recepteurs d'angiotensine et d'endotheline |
US20080318951A1 (en) * | 2007-06-05 | 2008-12-25 | Theravance, Inc. | Dual-acting benzoimidazole antihypertensive agents |
US20110009409A1 (en) * | 2009-07-07 | 2011-01-13 | Blair Brooke | Dual-acting pyrazole antihypertensive agents |
Non-Patent Citations (2)
Title |
---|
QUAN M L ET AL: "Balanced angiotensin II receptor antagonists. I. The effects of biphenyl ''ortho''-substitution on AT1/AT2 affinities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 4, no. 16, 25 August 1994 (1994-08-25), pages 2011 - 2016, XP026637436, ISSN: 0960-894X, [retrieved on 19940825], DOI: 10.1016/S0960-894X(01)80554-0 * |
See also references of WO2014145331A1 * |
Also Published As
Publication number | Publication date |
---|---|
ES2834430T3 (es) | 2021-06-17 |
DK2967049T3 (da) | 2020-12-07 |
KR102230461B1 (ko) | 2021-03-22 |
AU2014233185A1 (en) | 2015-10-29 |
CN105451554B (zh) | 2019-06-11 |
CA2911376A1 (fr) | 2014-09-18 |
EP2967049B1 (fr) | 2020-09-02 |
RU2015138801A (ru) | 2017-04-20 |
CA2911376C (fr) | 2021-03-30 |
US9732074B2 (en) | 2017-08-15 |
EP3935944A1 (fr) | 2022-01-12 |
NZ712479A (en) | 2019-01-25 |
KR20150138242A (ko) | 2015-12-09 |
US20180030042A1 (en) | 2018-02-01 |
CN105451554A (zh) | 2016-03-30 |
AU2014233185B2 (en) | 2018-03-15 |
HK1220324A1 (zh) | 2017-05-05 |
US20160016946A1 (en) | 2016-01-21 |
EP2967049A1 (fr) | 2016-01-20 |
WO2014145331A1 (fr) | 2014-09-18 |
US10301298B2 (en) | 2019-05-28 |
RU2688163C2 (ru) | 2019-05-20 |
JP6480909B2 (ja) | 2019-03-13 |
JP2016514702A (ja) | 2016-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
HK1220324A1 (zh) | 用於治療血管緊張素相關疾病的方法、化合物和組合物 | |
EP3082819A4 (fr) | Composés substitués de diaminopyrimidyle, compositions à base de ceux-ci, et méthodes de traitement les utilisant | |
EP3030323A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
EP3024497A4 (fr) | Procédés et compositions pour traiter des maladies du cerveau | |
EP3027192A4 (fr) | Méthodes permettant de traiter des tumeurs solides | |
EP3038610A4 (fr) | Compositions et méthodes pour le traitement de la presbytie | |
EP2988781A4 (fr) | Compositions et méthodes pour le traitement et le diagnostic de la grippe | |
EP3060041A4 (fr) | Composés de prostacycline, compositions en contenant et leurs procédés d'utilisation | |
EP2991670B8 (fr) | Utilisation de sobétirome dans le traitement de maladies associées à la myélinisation | |
IL241264A0 (en) | Compounds and compositions for the treatment of parasitic diseases | |
EP3019243A4 (fr) | Procédés pour traiter ou prévenir des états ophtalmologiques | |
EP2986113A4 (fr) | Compositions et méthodes pour le traitement des lésions cérébrales | |
EP3139928A4 (fr) | Compositions d'anordrine et méthodes de traitement de maladies | |
EP2994460A4 (fr) | Composés pour traiter des maladies médiées par l'angiogenèse | |
EP3004396A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3068387A4 (fr) | Composés et méthodes de traitement de la malaria | |
EP3062790A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
EP3169405A4 (fr) | Méthodes, composés et compositions pour le traitement de maladies musculo-squelettiques | |
HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
EP3082427A4 (fr) | Compositions et méthodes destinées à traiter le glaucome | |
EP3089745A4 (fr) | Composés, compositions et méthodes de traitement de cancers | |
EP2994147A4 (fr) | Compositions et méthodes pour le traitement des acouphènes | |
EP2991650A4 (fr) | Méthodes de traitement du cancer | |
EP2994156A4 (fr) | Composés, compositions et procédés permettant le traitement des maladies par inhibition de l'activité de tgf- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151009 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20161214 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/06 20060101ALI20161208BHEP Ipc: C07D 417/06 20060101ALI20161208BHEP Ipc: A61K 31/16 20060101ALI20161208BHEP Ipc: A01N 41/06 20060101AFI20161208BHEP Ipc: A61K 31/18 20060101ALI20161208BHEP Ipc: C07D 213/52 20060101ALI20161208BHEP Ipc: C07D 213/36 20060101ALI20161208BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1220324 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190214 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602014069707 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0041060000 Ipc: A61K0031427000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 213/52 20060101ALI20200214BHEP Ipc: A61K 31/4439 20060101ALI20200214BHEP Ipc: C07D 417/06 20060101ALI20200214BHEP Ipc: C07D 401/06 20060101ALI20200214BHEP Ipc: A61K 31/427 20060101AFI20200214BHEP Ipc: A61P 5/38 20060101ALI20200214BHEP Ipc: C07D 213/36 20060101ALI20200214BHEP Ipc: A61K 31/444 20060101ALI20200214BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200330 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1307995 Country of ref document: AT Kind code of ref document: T Effective date: 20200915 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014069707 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20201201 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201203 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201202 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: COSMOVICI INTELLECTUAL PROPERTY SARL, CH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210104 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210102 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014069707 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2834430 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210617 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210315 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1307995 Country of ref document: AT Kind code of ref document: T Effective date: 20200902 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230221 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230222 Year of fee payment: 10 Ref country code: FR Payment date: 20230222 Year of fee payment: 10 Ref country code: DK Payment date: 20230221 Year of fee payment: 10 Ref country code: AT Payment date: 20230222 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140315 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230222 Year of fee payment: 10 Ref country code: IT Payment date: 20230221 Year of fee payment: 10 Ref country code: GB Payment date: 20230221 Year of fee payment: 10 Ref country code: DE Payment date: 20230221 Year of fee payment: 10 Ref country code: BE Payment date: 20230221 Year of fee payment: 10 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230513 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200902 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230403 Year of fee payment: 10 Ref country code: CH Payment date: 20230401 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240222 Year of fee payment: 11 Ref country code: NL Payment date: 20240220 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20240222 Year of fee payment: 11 |